Erythropoietin's effect on lung fluid clearance in ARDS patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the impact of erythropoietin (EPO) on alveolar fluid clearance in patients diagnosed with acute respiratory distress syndrome (ARDS). It is designed as a double-blind, randomized controlled trial where participants will receive either EPO or a placebo while being monitored in an intensive care unit. The study aims to determine if EPO can accelerate the resolution of alveolar edema and improve hospital survival rates. Participants will be closely screened and randomized to ensure unbiased results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age≥18 years;
* Meeting diagnostic criteria for sepsis 3.0;
* Tracheal intubation and mechanical ventilation;
* Meeting the diagnostic criteria of ARDS Berlin;
* Willing to accept treatment and sign an informed consent form;

Exclusion Criteria:

* Age \<18 years;
* Pregnancy or lactation;
* Patients with malignant tumors;
* Recombinant human erythropoietin (rhEPO) allergic patients;
* Hemoglobin (Hb) ≥120g/L;
* have recently taken rhEPO (within 3 months) or participated in other clinical trials;
* History of thromboembolic disease (pulmonary embolism, heart attack, cerebral infarction, arteriovenous thrombosis);
* Inability or unwillingness to provide informed consent or to comply with the requirements of the study;

Where it's running

• SAHWenzhouMU
  Wenzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Shengwei Jin, Professor
• Email: jinshengwei69@163.com
• Phone: 13616663961

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Full-Course ECMO Pathway for Moderate-to-Severe ARDS

  This study tests a standardized, full-course ECMO management pathway to see if it improves care for adults with moderate-to-severe ARDS treated with VV-ECMO in real-world Chinese centers.

  Recruiting at 15 sites Southeast University, China · Beijing and 38 other locations · NCT07726953

• Height measurement methods to guide ventilator settings in ARDS

  We’re testing whether more precise height measurements change how researchers set lung-protective tidal volumes in adults with ARDS who are on a ventilator.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07595926

• Corticosteroids for a hyperinflammatory state in critical illness

  This trial tests whether methylprednisolone helps improve organ function and survival in adults with sepsis or ARDS who show a hyperinflammatory profile.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07511582

• Right‑heart function and heart–lung interaction during ARDS with mechanical ventilation

  This project will follow adults with ARDS on mechanical ventilation to see how positive‑pressure breathing affects the right heart over time and how that relates to circulation.

  Recruiting Bicetre Hospital · Le Kremlin-Bicêtre · NCT07450846

• Umbilical‑cord mesenchymal stem cell and secretome therapy for severe ARDS

  This trial tests whether IV umbilical‑cord mesenchymal stem cells, alone or with secretome, help adults with severe ARDS recover lung function and reduce inflammation.

  Recruiting Phase 1/2 PT. Prodia Stem Cell Indonesia · Jakarta Pusat, DKI Jakarta · NCT07439848

• Human umbilical cord mesenchymal stem cell injection for moderate to severe ARDS

  This will test whether a single injection of human umbilical cord mesenchymal stem cells can help adults with moderate to severe ARDS that hasn't improved after standard treatment.

  Recruiting Phase 1/2 Changchun Tuohua Pharmaceutical Co., Ltd. · Wuhan, Hubei · NCT07413978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.